Stifel Nicolaus Issues Pessimistic Forecast for Cooper Companies (NASDAQ:COO) Stock Price

Cooper Companies (NASDAQ:COO) had its price target decreased by equities researchers at Stifel Nicolaus from $115.00 to $105.00 in a report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the medical device company’s stock. Stifel Nicolaus’ price target suggests a potential upside of 25.51% from the stock’s previous close.

A number of other equities analysts have also recently weighed in on COO. Wells Fargo & Company upped their price target on Cooper Companies from $115.00 to $118.00 and gave the stock an “overweight” rating in a report on Friday, December 6th. Citigroup dropped their price target on Cooper Companies from $115.00 to $110.00 and set a “buy” rating for the company in a research report on Friday. Morgan Stanley lowered their price objective on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a research note on Friday, December 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of Cooper Companies in a research note on Friday. Finally, Robert W. Baird dropped their price target on shares of Cooper Companies from $117.00 to $107.00 and set an “outperform” rating for the company in a research note on Friday. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Cooper Companies currently has a consensus rating of “Moderate Buy” and an average price target of $111.89.

Cooper Companies Stock Performance

Shares of COO traded down $7.32 during mid-day trading on Friday, reaching $83.66. The company had a trading volume of 2,573,917 shares, compared to its average volume of 1,567,340. The stock has a 50 day moving average of $92.56 and a two-hundred day moving average of $99.51. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $16.70 billion, a P/E ratio of 42.82, a PEG ratio of 2.25 and a beta of 1.02. Cooper Companies has a 52-week low of $82.61 and a 52-week high of $112.38.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings data on Thursday, March 6th. The medical device company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The business had revenue of $964.70 million for the quarter, compared to analyst estimates of $981.25 million. On average, analysts expect that Cooper Companies will post 3.98 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in COO. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Cooper Companies during the fourth quarter worth about $17,392,000. Jefferies Financial Group Inc. lifted its holdings in Cooper Companies by 138.9% during the 4th quarter. Jefferies Financial Group Inc. now owns 48,514 shares of the medical device company’s stock worth $4,460,000 after buying an additional 28,204 shares during the last quarter. Mackenzie Financial Corp increased its stake in Cooper Companies by 12.4% in the fourth quarter. Mackenzie Financial Corp now owns 19,910 shares of the medical device company’s stock valued at $1,830,000 after purchasing an additional 2,193 shares during the last quarter. Forum Financial Management LP grew its holdings in shares of Cooper Companies by 107.3% during the fourth quarter. Forum Financial Management LP now owns 3,840 shares of the medical device company’s stock worth $353,000 after purchasing an additional 1,988 shares during the last quarter. Finally, Castlekeep Investment Advisors LLC acquired a new position in Cooper Companies during the fourth quarter worth approximately $685,000. 24.39% of the stock is currently owned by institutional investors and hedge funds.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.